未知生产厂商
Bucillamine is a thiol-based drug with antioxidant, anti-inflammatory and thiol-donating properties that has a history of clinical use for rheumatoid arthritis in Japan and South Korea. Revive Therapeutics is developing bucillamine for medical countermeasures (biodefence and pandemic preparedness) and rare diseases; it holds two U.S. FDA Orphan Drug Designations, for the treatment of cystinuria and for the prevention of ischemia-reperfusion injury during liver transplantation.
Bucillamine is a thiol-based drug with antioxidant, anti-inflammatory and thiol-donating properties that has a history of clinical use for rheumatoid arthritis in Japan and South Korea. Revive Therapeutics is developing bucillamine for medical countermeasures (biodefence and pandemic preparedness) and rare diseases; it holds two U.S. FDA Orphan Drug Designations, for the treatment of cystinuria and for the prevention of ischemia-reperfusion injury during liver transplantation.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
